52.61
-0.90 (-1.68%)
| Penutupan Terdahulu | 53.51 |
| Buka | 51.80 |
| Jumlah Dagangan | 1,802,301 |
| Purata Dagangan (3B) | 2,048,036 |
| Modal Pasaran | 5,013,745,152 |
| Harga / Pendapatan (P/E Ke hadapan) | 23.36 |
| Harga / Jualan (P/S) | 133.72 |
| Harga / Buku (P/B) | 2.66 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -17,158.84% |
| EPS Cair (TTM) | -4.49 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 71.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 11.99% |
| Nisbah Semasa (MRQ) | 15.64 |
| Aliran Tunai Operasi (OCF TTM) | -306.47 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -193.24 M |
| Pulangan Atas Aset (ROA TTM) | -12.88% |
| Pulangan Atas Ekuiti (ROE TTM) | -19.71% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | CRISPR Therapeutics AG | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -3.5 |
| Purata | -2.13 |
|
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Value |
| % Dimiliki oleh Orang Dalam | 1.69% |
| % Dimiliki oleh Institusi | 76.46% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 86.00 (Citizens, 63.47%) | Beli |
| Median | 75.50 (43.51%) | |
| Rendah | 44.00 (Baird, -16.37%) | Pegang |
| Purata | 68.50 (30.20%) | |
| Jumlah | 4 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 54.81 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citizens | 23 Dec 2025 | 86.00 (63.47%) | Beli | 56.46 |
| Needham | 23 Dec 2025 | 80.00 (52.06%) | Beli | 56.46 |
| 10 Nov 2025 | 80.00 (52.06%) | Beli | 54.58 | |
| Chardan Capital | 26 Nov 2025 | 74.00 (40.66%) | Beli | 53.30 |
| Citigroup | 12 Nov 2025 | 77.00 (46.36%) | Beli | 52.19 |
| Baird | 11 Nov 2025 | 44.00 (-16.37%) | Pegang | 55.21 |
| RBC Capital | 11 Nov 2025 | 50.00 (-4.96%) | Pegang | 55.21 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones |
| 05 Jan 2026 | Pengumuman | CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 02 Jan 2026 | Pengumuman | Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize |
| 22 Dec 2025 | Pengumuman | CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies |
| 09 Dec 2025 | Pengumuman | Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions |
| 10 Nov 2025 | Pengumuman | CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results |
| 08 Nov 2025 | Pengumuman | CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |